CAS number：1627091-47-7 molecular formula：C21H25N5O2
MLi-2 是一种结构新颖、高效、选择性的 LRRK2 激酶抑制剂，具有中枢神经系统活性，IC50为 0.76 nM，有潜力用于帕金森氏病。 MLi-2 is a structurally novel, highly potent, and selective LRRK2 kinase inhibitor with central nervous system activity. MLi-2 exhibits exceptional potency in a purified LRRK2 kinase assay in vitro (IC50 = 0.76 nM), a cellular assay monitoring dephosphorylation of LRRK2 pSer935 LRRK2 (IC50 = 1.4 nM), and a radioligand competition binding assay (IC50 = 3.4 nM).
| Chinese alias | (2R,6S)-2,6-二甲基-4-[6-[5-(1-(甲基环丙基)氧基]-1H-吲唑-3-基]嘧啶-4-基]吗啉 | ||
| English alias | (2R,6S)-2,6-Dimethyl-4-[6-[5-(1-methylcyclopropyl)oxy-1H-indazol-3-yl]pyrimidin-4-yl]morpholine | cis-2,6-Dimethyl-4-(6-(5-(1-methylcyclopropoxy)-1H-indazol-3-yl)pyrimidin-4-yl)morpholine | rel-3-[6-[(2R,6S)-2,6-Dimethyl-4-morpholinyl]-4-pyrimidinyl]-5-[( | ||
| CAS number | 1627091-47-7 | molecular formula | C21H25N5O2 |
| molecular weight | 379.46 g/mol | Exact mass | - |
| PSA | 76.200 Ų | logp | 3.2 |
No numbering system information yet
No physical and chemical property information yet
No safety information yet
No production method and use information yet
No upstream information yet
No downstream information yet
